ProCE Banner Activity

DISCOVER: Phase III Study of Emtricitabine/Tenofovir Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate for HIV PrEP

Slideset Download
Conference Coverage
Daily oral PrEP with FTC/TAF is noninferior to FTC/TDF in preventing HIV infection in cis-MSM and transgender women at high risk for HIV acquisition.

Released: March 11, 2019

Expiration: March 09, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare